Skip to content
Screener

uniQure QURE Stock-Based Comp

Stock-Based Comp at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$24.47M-33.9%
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
$5.55M+68.4%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$23.42M+29.7%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$3.92M+10.9%
Candel Therapeutics, Inc. logo
Candel Therapeutics, Inc.CADL
$1.45M+362%
Regenxbio logo
RegenxbioRGNX
$9.05M+4.6%

Segments

By segment

See full
Single Reportable$5.02M-1.3%

Other financials

Income statement

See full
Revenue$5.8M+11.0%
Gross profit$5.5M+19.2%
Operating income-$52.2M-19.0%
Net income-$81.1M-115%
EPS (diluted)-$1.22-76.8%

Balance sheet

See full
Cash & equivalents$413.0M+62.8%
Total debt$62.8M-5.8%
Total equity$324.1M+8,195%
Total assets$985.1M+68.4%

Cash flow

See full
Operating cash flow-$28.6M+28.4%
CapEx$472.0K+81.5%
Free cash flow-$29.0M+27.7%

Valuation

See full
Market cap$3.15B+325%
Enterprise value$2.8B+406%
P/S168.5×+117×

Profitability

See full
Gross margin92.5%+4.6pp
Operating margin-1,071.5%-90.6pp
Net margin-1,350.7%-35.3pp
FCF margin-864.7%-194pp

Returns & leverage

See full
Return on equity-228.2%-11.6pp
Debt / equity0.2×
Current ratio10×0.0×

Where this comes from

Reported directly by uniQure in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The source filing: uniQure’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 7:17 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-087815
Line itemSix months ended June 30, 2026Six months ended June 30, 2025
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization7,8638,157
Amortization of discount on investment securities(7,907)(4,163)
Share-based compensation expense10,1069,494
Royalty financing agreement interest expense, net of interest paid17,38420,626
Deferred tax expense2,329921
Changes in fair value of contingent consideration(82)3,470
Changes in fair value of liability related to pre-funded warrants12,201

Item 1.Financial Statements

FAQ

What is uniQure's stock-based comp?
uniQure (QURE) reported stock-based comp of $5.02M in Q2 2026.
How has uniQure's stock-based comp changed year-over-year?
uniQure's stock-based comp decreased by 1.3% year-over-year, from $5.08M to $5.02M.
What is the long-term trend for uniQure's stock-based comp?
Over 4 years (2021 to 2025), uniQure's stock-based comp has grown at a -8.9% compound annual growth rate (CAGR), from $25.64M to $17.68M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Ask your AI about uniQure's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude